(Q38130168)

29 August 2017

title

Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how. (English)

1 reference

stem cell transplantation

29 August 2017

main subject

1 reference

1 reference

acute myeloid leukemia

1 reference

John Magenau

1

1 reference

29 August 2017

Daniel R Couriel

series ordinal

2

1 reference

29 August 2017

publication date

1 October 2013

1 reference

29 August 2017

published in

Current Oncology Reports

1 reference

29 August 2017

volume

15

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

436-444

1 reference

Acute myeloid leukemia in first remission: to choose transplantation or not?

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Reduced mortality after allogeneic hematopoietic-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Genetic profiling in acute myeloid leukaemia--where are we and what is its role in patient management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis fro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and mu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0340-6

The prevalent predicament of relapsed acute myeloid leukemia

21 January 2018

1 reference

12 December 2020

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

12 December 2020

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

1 reference

12 December 2020

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

1 reference

12 December 2020

Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.

1 reference

12 December 2020

CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT

1 reference

12 December 2020

Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy

1 reference

12 December 2020

Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories

1 reference

12 December 2020

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

1 reference

12 December 2020

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission

1 reference

12 December 2020

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies

1 reference

12 December 2020

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission

1 reference

12 December 2020

Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia – a useful tool for early detection of minimal residual disease

1 reference

12 December 2020

Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia

1 reference

12 December 2020

Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT

1 reference

12 December 2020

Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system

1 reference

12 December 2020

10.1007/S11912-013-0340-6

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1049529410

0 references

1 reference